ONLINE FIRST (FREE ACCESS) LATEST ARTICLES EditorialIntensive Care Medicine facing the futureCiterio G. OriginalCircular material flow in the intensive care unit—environmental effects and identification of hotspotsHunfeld N. et al. Association between acute disease severity and one-year quality of life among post-hospitalisation COVID-19 patients: Coalition VII prospective cohort studyRosa R.G. et al. Relationship between immunosuppression and intensive car...

ARTICLES|ONLINE FIRST Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study Jose Villar, Constanza P Soto Conti, Robert B Gunier, et al Lancet Published:January 17, 2023 DOI:https://doi.org/10.1016/S0140-6736(22)02467-9 Summary Background In 2021, we showed an increased risk associated with COVID-19 in pregnancy. Since then, the SARS-CoV-2 virus has un...

ORIGINAL ARTICLE Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture Major Extremity Trauma Research Consortium (METRC) N Engl J Med 2023; 388:203-213DOI: 10.1056/NEJMoa2205973 Abstract BACKGROUND Clinical guidelines recommend low-molecular-weight heparin for thromboprophylaxis in patients with fractures, but trials of its effectiveness as compared with aspirin are lacking. METHODS In this pragmatic, multicenter, randomi...

Original Investigation  January 12, 2023 Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial Matthew W. McCarthy, Susanna Naggie, David R. Boulware, et al JAMA. Published online January 12, 2023. doi:10.1001/jama.2022.24100 Key Points Question  Does 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, shorten symptom duration amo...

NEWS 18 January 2023 ChatGPT listed as author on research papers: many scientists disapprove At least four articles credit the AI tool as a co-author, as publishers scramble to regulate its use. Chris Stokel-Walker Nature 613, 620-621 (2023) doi: https://doi.org/10.1038/d41586-023-00107-z The artificial-intelligence chatbot ChatGPT is disrupting many industries, including academia.Credit: Iryna Imago/Shutterstock The artificial-intelligence (AI) ...

Research Letter  January 17, 2023 Timing of Blood Draws Among Patients Hospitalized in a Large Academic Medical Center César Caraballo, Shiwani Mahajan, Karthik Murugiah, et al JAMA. 2023;329(3):255-257. doi:10.1001/jama.2022.21509 Sleep is a key element of patient care and experience, and its deprivation among hospitalized patients is an important stressor that increases their risk of adverse events during and after hospitalization.1-3&...

Original Investigation  Caring for the Critically Ill Patient January 17, 2023 Effect of Early High-Flow Nasal Oxygen vs Standard Oxygen Therapy on Length of Hospital Stay in Hospitalized Children With Acute Hypoxemic Respiratory Failure: The PARIS-2 Randomized Clinical Trial Donna Franklin, Franz E. Babl, Shane George, et al JAMA. 2023;329(3):224-234. doi:10.1001/jama.2022.21805 Key Points Question  Does the early use of nasa...

Original Investigation  January 17, 2023 Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial Robert J. Mentz, Kevin J. Anstrom, Eric L. Eisenstein, et al JAMA. 2023;329(3):214-223. doi:10.1001/jama.2022.23924 Key Points Question  Does torsemide reduce all-cause mortality compared with furosemide in patients with heart fail...

ORIGINAL ARTICLE Early Treatment with Pegylated Interferon Lambda for Covid-19 Gilmar Reis, Eduardo A.S. Moreira Silva, Daniela C. Medeiros Silva, et al N Engl J Med 2023; 388:518-528DOI: 10.1056/NEJMoa2209760 Abstract BACKGROUND The efficacy of a single dose of pegylated interferon lambda in preventing clinical events among outpatients with acute symptomatic coronavirus disease 2019 (Covid-19) is unclear. METHODS We conducted a randomized, control...

ARTICLES| VOLUME 11, ISSUE 1, P87-96, JANUARY 01, 2023 Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study Joshua J Solomon, Sonye K Danoff, Felix A Woodhead, et al. Lancet Respir Med 2023; 11: 87-96 Published:September 05, 2022 DOI:https://doi.org/10.1016/S2213-2600(22)00260-0 Summary Background Inters...